今年第17届圣加伦（SG）早期乳腺癌患者治疗共识会议（SG-BCC）的标题为“为早期乳腺癌女性定制局部和全身疗法”，重点关注了针对早期乳腺癌治疗的挑战，更具体地针对每位患者的个体疾病情况。和往年一样,德国领先的乳腺癌专家工作组在德国指南的背景下讨论了国际SG-BCC2021的结果.将SG建议与德国妇科肿瘤学工作组乳房委员会最近更新的治疗建议（ArbeitsgemeinschaftGynkologischeOnkologiee。,AGO)和S3指南，因为SG-BCC小组由来自不同国家的专家组成，这就是为什么特定国家的方面可以纳入SG建议。德国AGO和S3指南的治疗建议是基于目前的证据。然而，任何治疗决策都必须针对具体情况进行风险-收益分析,并与患者讨论.
This year\'s 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title \"Customizing local and systemic therapies for women with early breast cancer\" focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e. V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.
PDF(Pubmed)